These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 28768759)

  • 41. Economic Outcomes of Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention: 1-Year Results From the ABSORB III Trial.
    Baron SJ; Lei Y; Chinnakondepalli K; Vilain K; Magnuson EA; Kereiakes DJ; Ellis SG; Stone GW; Cohen DJ;
    JACC Cardiovasc Interv; 2017 Apr; 10(8):774-782. PubMed ID: 28427593
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bioresorbable Vascular Scaffolds for Coronary Revascularization.
    Kereiakes DJ; Onuma Y; Serruys PW; Stone GW
    Circulation; 2016 Jul; 134(2):168-82. PubMed ID: 27400899
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Coronary bifurcations: still the touchstone of drug-eluting stents and bioresorbable vascular scaffolds?
    von Birgelen C; van Houwelingen KG; Lam MK
    Rev Esp Cardiol (Engl Ed); 2014 Oct; 67(10):787-9. PubMed ID: 25262123
    [No Abstract]   [Full Text] [Related]  

  • 44. Bioresorbable vascular scaffolds for the treatment of coronary artery disease: Clinical outcomes from randomized controlled trials.
    Rizik DG; Hermiller JB; Kereiakes DJ
    Catheter Cardiovasc Interv; 2016 Nov; 88(S1):21-30. PubMed ID: 27797464
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term outcome of bioresorbable vascular scaffolds for the treatment of coronary artery disease: a meta-analysis of RCTs.
    Polimeni A; Anadol R; Münzel T; Indolfi C; De Rosa S; Gori T
    BMC Cardiovasc Disord; 2017 Jun; 17(1):147. PubMed ID: 28592227
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis.
    Kang SH; Park KW; Kang DY; Lim WH; Park KT; Han JK; Kang HJ; Koo BK; Oh BH; Park YB; Kandzari DE; Cohen DJ; Hwang SS; Kim HS
    Eur Heart J; 2014 May; 35(17):1147-58. PubMed ID: 24459196
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Initial experience with everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with acute myocardial infarction: a propensity-matched comparison to metallic drug eluting stents 18-month follow-up of the BVS STEMI first study.
    Fam JM; Felix C; van Geuns RJ; Onuma Y; Van Mieghem NM; Karanasos A; van der Sijde J; De Paolis M; Regar E; Valgimigli M; Daemen J; de Jaegere P; Zijlstra F; Diletti R
    EuroIntervention; 2016 May; 12(1):30-7. PubMed ID: 27173859
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intraindividual Comparison of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Drug-Eluting Metallic Stents.
    Cassese S; Hoppmann P; Kufner S; Byrne RA; Wiebe J; Colleran R; Giacoppo D; Harada Y; Laugwitz KL; Schunkert H; Fusaro M; Kastrati A
    Circ Cardiovasc Interv; 2016 Aug; 9(8):. PubMed ID: 27512088
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of everolimus and zotarolimus-eluting stents versus first-generation drug-eluting stents in patients with diabetes: A meta-analysis of randomized trials.
    Bavishi C; Baber U; Panwar S; Pirrotta S; Dangas GD; Moreno P; Tamis-Holland J; Kini AS; Sharma SK
    Int J Cardiol; 2017 Mar; 230():310-318. PubMed ID: 28062139
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bioresorbable scaffolds compared with everolimus-eluting stents for the treatment of chronic coronary total occlusion: clinical and angiographic results of a matched paired comparison.
    Kugler C; Markovic S; Rottbauer W; Wöhrle J
    Coron Artery Dis; 2017 Mar; 28(2):120-125. PubMed ID: 27845998
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Randomised comparison of a bioresorbable everolimus-eluting scaffold with a metallic everolimus-eluting stent for ischaemic heart disease caused by de novo native coronary artery lesions: the 2-year clinical outcomes of the ABSORB II trial.
    Chevalier B; Onuma Y; van Boven AJ; Piek JJ; Sabaté M; Helqvist S; Baumbach A; Smits PC; Kumar R; Wasungu L; Serruys PW
    EuroIntervention; 2016 Oct; 12(9):1102-1107. PubMed ID: 27564310
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Risk and timing of clinical events according to diabetic status of patients treated with everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting stent: 2-year results from a propensity score matched comparison of ABSORB EXTEND and SPIRIT trials.
    Campos CM; Caixeta A; Franken M; Bartorelli AL; Whitbourn RJ; Wu CJ; Li Paul Kao H; Rosli MA; Carrie D; De Bruyne B; Stone GW; Serruys PW; Abizaid A;
    Catheter Cardiovasc Interv; 2018 Feb; 91(3):387-395. PubMed ID: 28471086
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Arterial healing following primary PCI using the Absorb everolimus-eluting bioresorbable vascular scaffold (Absorb BVS) versus the durable polymer everolimus-eluting metallic stent (XIENCE) in patients with acute ST-elevation myocardial infarction: rationale and design of the randomised TROFI II study.
    Räber L; Onuma Y; Brugaletta S; Garcia-Garcia HM; Backx B; Iñiguez A; Okkels Jensen L; Cequier-Fillat À; Pilgrim T; Christiansen EH; Hofma SH; Suttorp M; Serruys PW; Sabaté M; Windecker S
    EuroIntervention; 2016 Jul; 12(4):482-9. PubMed ID: 26342471
    [TBL] [Abstract][Full Text] [Related]  

  • 55. One-year clinical outcomes of patients treated with everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a propensity score comparison of patients enrolled in the ABSORB EXTEND and SPIRIT trials.
    de Ribamar Costa J; Abizaid A; Bartorelli AL; Whitbourn R; Jepson N; Perin M; Steinwender C; Stuteville M; Ediebah D; Sudhir K; Serruys PW
    EuroIntervention; 2016 Nov; 12(10):1255-1262. PubMed ID: 27866134
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Letter by Dérimay et al. regarding the article, "A randomized trial comparing two stent sizing strategies in coronary bifurcation treatment with bioresorbable vascular scaffolds - The Absorb Bifurcation Coronary (ABC) trial" by Rampat et al.
    Dérimay F; Rioufol G; Finet G
    Cardiovasc Revasc Med; 2019 Jan; 20(1):85-86. PubMed ID: 30236626
    [No Abstract]   [Full Text] [Related]  

  • 57. Implantation of everolimus-eluting bioresorbable scaffolds in a diabetic all-comers population--the future is now?
    Sharma AK; Levy MS
    Catheter Cardiovasc Interv; 2015 Nov; 86(6):982-3. PubMed ID: 26541799
    [No Abstract]   [Full Text] [Related]  

  • 58. Is the Metallic Stent a Safe Treatment for Bioresorbable Scaffold Failure?: Insights From Optical Coherence Tomography.
    Capranzano P; Francaviglia B; Capodanno D; Buccheri S; Tamburino CI; Gargiulo G; Tamburino C
    JACC Cardiovasc Interv; 2016 May; 9(9):976-7. PubMed ID: 27085571
    [No Abstract]   [Full Text] [Related]  

  • 59. In reply to: Letter by Dérimay et al. regarding the article, "A randomized trial comparing two stent sizing strategies in coronary bifurcation treatment with bioresorbable vascular scaffolds - The Absorb Bifurcation Coronary (ABC) trial" by Rampat et al.
    Rampat R; Mayo T; Hildick-Smith D; Cockburn J
    Cardiovasc Revasc Med; 2019 Jan; 20(1):86. PubMed ID: 30463797
    [No Abstract]   [Full Text] [Related]  

  • 60. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
    Claessen BE; Smits PC; Kereiakes DJ; Parise H; Fahy M; Kedhi E; Serruys PW; Lansky AJ; Cristea E; Sudhir K; Sood P; Simonton CA; Stone GW
    JACC Cardiovasc Interv; 2011 Nov; 4(11):1209-15. PubMed ID: 22115661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.